Navigation Links
Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
Date:5/23/2011

LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, today announced that former California Governor, Gray Davis, has joined the company as Chairman of its Corporate Advisory Board. Governor Davis is committed to the improvement of healthcare and advancement of medical technologies.

During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels of funding in the country for cancer and HIV research and treatment. Governor Davis set the most stringent standards for cancer clinical trials and made history by enrolling more children in the federal children's health insurance program (Healthy Families) than any state previously had.  He is currently Of Counsel at the Los Angeles office of law firm Loeb & Loeb.

"I believe personalized medicine is the future – and holds great promise for those suffering from chronic diseases," stated Governor Davis.

Genesis Biopharma Chairman and CEO, Anthony J. Cataldo, added, "Governor Davis brings tremendous value and insight as a person who has implemented his vision for a better healthcare system through advancements in technology and policy. He offers us his experience in organizational leadership, as well as his knowledge in working with regulatory bodies to help  bring our cancer therapies to market to save lives, reduce healthcare costs, and keep America at the forefront of innovative therapeutics."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
2. Governor OMalley Announces State Grants Available For Maryland Bio Companies
3. Howard J. Leonhardt Announces Candidacy for Governor of California
4. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
5. Venture Capitalists to Invest in Promising PA Life Science Companies, Governor Rendell Says
6. The Biotechnology Industry Organization Honors Georgia Governor Sonny Perdue as Governor of the Year
7. Governor Rendell Says Life Science Industry Will Fuel New Breakthroughs, Generate Jobs for Decades to Come
8. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
9. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
10. Tengion Appoints A. Brian Davis Chief Financial Officer
11. Davis Phinney Foundation Launches Every Victory Counts Program to Inform and Empower People to Live Well With Parkinsons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Baltimore, MD (PRWEB) , ... April 27, 2017 ... ... analytics solutions provider for digital pathology, today announced their digital pathology technology has ... Using images provided by five medical centers in The Netherlands as part of ...
(Date:4/27/2017)... ... 27, 2017 , ... Sierra Instruments announces the ... thermal mass flow technology provide exponentially more accurate mass flow data than volumetric ... all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, and HVAC—require ...
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio tech firm, ... security screening solution at the National Postal Forum 2017 in Baltimore, Maryland, May ... highly accurate, easy to use and low cost threat detection solution for government ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):